1. Within your trust how many patients over the last 12 months (November 2019 to October 2020 or latest available) have received the following anti-VEGF treatments:
• Aflibercept
• Bevacizumab
• Brolucizumab
• Dexamethasone
• Fluocinolone acetonide
• Ranibizumab
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
• Aflibercept
• Bevacizumab
• Brolucizumab
• Dexamethasone
• Fluocinolone acetonide
• Ranibizumab
Download response anti-VEFG treatments for eye conditions. 161220